Imiquimod 5% cream is approved for the topical treatment of external anogenital warts
caused by human papillomavirus (HPV) and for the skin cancer conditions superficial basal …

Imiquimod : Current Opinion in Infectious Diseases Imiquimod : Current Opinion in Infectious
Diseases Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts …

Objective Clinical efficacy and safety of Polyphenon® E, a defined green tea extract, in
external genital warts. Design Randomized, double‐blind, placebo‐controlled study for up to …

Anogenital warts and mollusca contagiosum are virally induced, benign skin tumors for
which there is no single preferable therapy. Treatments include physical and chemical …

Background Anogenital warts (AGWs, condylomata acuminata) are among the most
common STIs and may severely impact quality of life (QoL). Available treatment options are …

Background 30% of people with anogenital warts (AGW) have spontaneous regression of
lesions but there is no way to determine whether a specific lesion will remain. There are a …

Objective To evaluate the value of 85% trichloroacetic acid (TCA) in the treatment of human
papillomavirus (HPV)-associated genital warts of the external genitalia and to detect the …

Increased anorectal human papillomavirus (HPV) infection is related to the recent trends in
sexual behavior in both homosexual and heterosexual groups and prevalence of infection …

Imiquimod 5% cream (Aldara, Graceway Pharmaceuticals) is an immune response modifier
used for the topical treatment of anogenital warts in non-HIV-infected patients. Several …

Patients with condyloma acuminata (CA) during pregnancy represent a special risk group.
The outcomes of many treatment methods for such cases are not satisfactory. The purpose …